The company is expanding its scientific advisory base as part of our upcoming seed-stage growth phase. Newly added advisors bring expertise in tumor immunology, structural biology, and translational oncology. Their guidance will help shape our roadmap as we prepare for platform validation studies and early partner programs.
Additional details, including advisor bios and program timelines, will be published soon.